Search

Your search keyword '"Singal, Amit G."' showing total 2,061 results
Start Over Author "Singal, Amit G."
2,061 results on '"Singal, Amit G."'

4. The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma: a phase 2 trial

Author

Hsiehchen, David, Beg, Muhammad S., Kainthla, Radhika, Lohrey, Jay, Kazmi, Syed M., Khosama, Leticia, Maxwell, Mary Claire, Kline, Heather, Katz, Courtney, Hassan, Asim, Kubota, Naoto, Siglinsky, Ellen, Pillai, Anil K., Youssoufian, Hagop, Mockbee, Colleen, Culm, Kerry, Uhlik, Mark, Benjamin, Laura, Brekken, Rolf A., Ahn, Chul, Singal, Amit G., Zhu, Hao, Hoshida, Yujin, and Yopp, Adam C.

Published
2024
Full Text
View/download PDF

6. Recall patterns and risk of primary liver cancer for subcentimeter ultrasound liver observations: a multicenter study.

Author

Singal, Amit G, Ghaziani, T Tara, Mehta, Neil, Zhou, Kali, Grinspan, Lauren T, Benhammou, Jihane N, Moon, Andrew M, Yang, Ju Dong, Salgia, Reena, Pillai, Anjana, Zheng, Elizabeth, Rich, Nicole E, Gopal, Purva, Jalal, Prasun, Verna, Elizabeth, Yekkaluri, Sruthi, Phen, Samuel, Melendez-Torres, Jonathan, Alshuwaykh, Omar, Choi, Hailey, Junus, Kevin, Grady, John, Song, Michael, Leven, Emily A, Yum, Jung, Gowda, Vrushab, Alsudaney, Manaf, Hernandez, Perla, Desai, Nirmal, and Parikh, Neehar D

Subjects
Bile Ducts, Intrahepatic, Humans, Carcinoma, Hepatocellular, Bile Duct Neoplasms, Liver Neoplasms, Liver Cirrhosis, alpha-Fetoproteins, Retrospective Studies, Digestive Diseases, Biomedical Imaging, Cancer, Clinical Research, Liver Disease, Prevention, Hepatitis, Liver Cancer, Chronic Liver Disease and Cirrhosis, Rare Diseases, Good Health and Well Being
Abstract

BackgroundPatients with cirrhosis and subcentimeter lesions on liver ultrasound are recommended to undergo short-interval follow-up ultrasound because of the presumed low risk of primary liver cancer (PLC).AimsThe aim of this study is to characterize recall patterns and risk of PLC in patients with subcentimeter liver lesions on ultrasound.MethodsWe conducted a multicenter retrospective cohort study among patients with cirrhosis or chronic hepatitis B infection who had subcentimeter ultrasound lesions between January 2017 and December 2019. We excluded patients with a history of PLC or concomitant lesions ≥1 cm in diameter. We used Kaplan Meier and multivariable Cox regression analyses to characterize time-to-PLC and factors associated with PLC, respectively.ResultsOf 746 eligible patients, most (66.0%) had a single observation, and the median diameter was 0.7 cm (interquartile range: 0.5-0.8 cm). Recall strategies varied, with only 27.8% of patients undergoing guideline-concordant ultrasound within 3-6 months. Over a median follow-up of 26 months, 42 patients developed PLC (39 HCC and 3 cholangiocarcinoma), yielding an incidence of 25.7 cases (95% CI, 6.2-47.0) per 1000 person-years, with 3.9% and 6.7% developing PLC at 2 and 3 years, respectively. Factors associated with time-to-PLC were baseline alpha-fetoprotein >10 ng/mL (HR: 4.01, 95% CI, 1.85-8.71), platelet count ≤150 (HR: 4.90, 95% CI, 1.95-12.28), and Child-Pugh B cirrhosis (vs. Child-Pugh A: HR: 2.54, 95% CI, 1.27-5.08).ConclusionsRecall patterns for patients with subcentimeter liver lesions on ultrasound varied widely. The low risk of PLC in these patients supports short-interval ultrasound in 3-6 months, although diagnostic CT/MRI may be warranted for high-risk subgroups such as those with elevated alpha-fetoprotein levels.

Published
2023

11. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer

Author

Huang, Daniel Q, Singal, Amit G, Kono, Yuko, Tan, Darren JH, El-Serag, Hashem B, and Loomba, Rohit

Subjects
Rare Diseases, Hepatitis - C, Alcoholism, Alcohol Use and Health, Liver Cancer, Chronic Liver Disease and Cirrhosis, Emerging Infectious Diseases, Digestive Diseases, Infectious Diseases, Substance Misuse, Liver Disease, Cancer, Hepatitis - B, Hepatitis, 2.4 Surveillance and distribution, Aetiology, Oral and gastrointestinal, Infection, Good Health and Well Being, Hepatitis C, Humans, Liver Neoplasms, Non-alcoholic Fatty Liver Disease, Obesity, Risk Factors, United States, alcohol, epidemiology, etiology, hepatitis B, hepatitis C, hepatocellular carcinoma, hepatoma, liver cancer, nonalcoholic steatohepatitis, Biochemistry and Cell Biology, Medical Biochemistry and Metabolomics, Endocrinology & Metabolism
Abstract

Liver cancer epidemiology is changing due to increasing alcohol consumption, rising prevalence of obesity, and advances in hepatitis B virus (HBV) and hepatitis C virus (HCV) treatment. However, the impact of these changes on global liver cancer burden remains unclear. We estimated global and regional temporal trends in the burden of liver cancer and the contributions of various liver disease etiologies using the methodology framework of the Global Burden of Disease study. Between 2010 and 2019, there was a 25% increase in liver cancer deaths. Age-standardized death rates (ASDRs) increased only in the Americas and remained stable or fell in all other regions. Between 2010 and 2019, non-alcoholic steatohepatitis (NASH) and alcohol had the fastest growing ASDRs, while HCV and HBV declined. Urgent measures are required at a global level to tackle underlying metabolic risk factors and slow the growing burden of NASH-associated liver cancer, especially in the Americas.

Published
2022

19. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

Author

Reig, Maria, Forner, Alejandro, Rimola, Jordi, Ferrer-Fàbrega, Joana, Burrel, Marta, Garcia-Criado, Ángeles, Kelley, Robin K, Galle, Peter R, Mazzaferro, Vincenzo, Salem, Riad, Sangro, Bruno, Singal, Amit G, Vogel, Arndt, Fuster, Josep, Ayuso, Carmen, and Bruix, Jordi

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Cancer, Rare Diseases, Liver Disease, Liver Cancer, Digestive Diseases, Clinical Trials and Supportive Activities, Good Health and Well Being, Carcinoma, Hepatocellular, Female, Humans, Liver Neoplasms, Male, Middle Aged, Neoplasm Staging, Prognosis, Severity of Illness Index, HCC, survival, BCLC, ablation, surgery, liver transplantation TACE, TARE, systemic treatment, ALBI score, AFP, Clinical Sciences, Public Health and Health Services, Gastroenterology & Hepatology, Clinical sciences
Abstract

There have been major advances in the armamentarium for hepatocellular carcinoma (HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and treatment strategy published in 2018. Whilst there have been advances in all areas, we will focus on those that have led to a change in strategy and we will discuss why, despite being encouraging, data for select interventions are still too immature for them to be incorporated into an evidence-based model for clinicians and researchers. Finally, we describe the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.

Published
2022

20. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

Author

Celsa, Ciro, Cabibbo, Giuseppe, Fulgenzi, Claudia A.M., Scheiner, Bernhard, D’Alessio, Antonio, Manfredi, Giulia F., Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Saeed, Anwaar, Wietharn, Brooke, Pinter, Matthias, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, Phen, Samuel, Gampa, Anuhya, Pillai, Anjana, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Roehlen, Natascha, Thimme, Robert, Vogel, Arndt, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Galle, Peter R., Kudo, Masatoshi, Rimassa, Lorenza, Singal, Amit G., El Tomb, Paul, Ulahannan, Susanna, Parisi, Alessandro, Chon, Hong Jae, Hsu, Wei-Fan, Stefanini, Bernardo, Verzoni, Elena, Giusti, Raffaele, Veccia, Antonello, Catino, Annamaria, Aprile, Giuseppe, Guglielmini, Pamela Francesca, Di Napoli, Marilena, Ermacora, Paola, Antonuzzo, Lorenzo, Rossi, Ernesto, Verderame, Francesco, Zustovich, Fable, Ficorella, Corrado, Di Pietro, Francesca Romana, Battelli, Nicola, Negrini, Giorgia, Grossi, Francesco, Bordonaro, Roberto, Pipitone, Stefania, Banzi, Maria, Ricciardi, Serena, Laera, Letizia, Russo, Antonio, De Giorgi, Ugo, Cavanna, Luigi, Sorarù, Mariella, Montesarchio, Vincenzo, Bordi, Paola, Brunetti, Leonardo, Pinto, Carmine, Bersanelli, Melissa, Cammà, Calogero, Cortellini, Alessio, and Pinato, David J.

Published
2024
Full Text
View/download PDF

21. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Author

Balcar, Lorenz, Scheiner, Bernhard, Fulgenzi, Claudia Angela Maria, D’Alessio, Antonio, Pomej, Katharina, Roig, Marta Bofill, Meyer, Elias Laurin, Che, Jaekyung, Nishida, Naoshi, Lee, Pei-Chang, Wu, Linda, Ang, Celina, Krall, Anja, Saeed, Anwaar, Stefanini, Bernardo, Cammarota, Antonella, Pressiani, Tiziana, Abugabal, Yehia I., Chamseddine, Shadi, Wietharn, Brooke, Parisi, Alessandro, Huang, Yi-Hsiang, Phen, Samuel, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Bettinger, Dominik, Vogel, Arndt, von Felden, Johann, Schulze, Kornelius, Silletta, Marianna, Trauner, Michael, Samson, Adel, Wege, Henning, Piscaglia, Fabio, Galle, Peter R., Stauber, Rudolf, Kudo, Masatoshi, Singal, Amit G., Itani, Aleena, Ulahannan, Susanna V., Parikh, Neehar D., Cortellini, Alessio, Kaseb, Ahmed, Rimassa, Lorenza, Chon, Hong Jae, Pinato, David J., and Pinter, Matthias

Published
2024
Full Text
View/download PDF

23. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis

Author

Rezaee-Zavareh, Mohammad Saeid, Yeo, Yee Hui, Wang, Tielong, Guo, Zhiyong, Tabrizian, Parissa, Ward, Stephen C., Barakat, Fatma, Hassanein, Tarek I., Shravan, Dave, Veeral, Ajmera, Bhoori, Sherrie, Mazzaferro, Vincenzo, Chascsa, David M.H., Liu, Margaret C., Aby, Elizabeth S., Lake, John R., Sogbe, Miguel, Sangro, Bruno, Abdelrahim, Maen, Esmail, Abdullah, Schmiderer, Andreas, Chouik, Yasmina, Rudolph, Mark, Sohal, Davendra, Giudicelli, Heloise, Allaire, Manon, Akce, Mehmet, Guadagno, Jessica, Tow, Clara Y., Massoumi, Hatef, De Simone, Paolo, Kang, Elise, Gartrell, Robyn D., Martinez, Mercedes, Paz-Fumagalli, Ricardo, Toskich, Beau B., Tran, Nguyen H., Solino, Gabriela Azevedo, Poltronieri Pacheco, Dra Mariana, Kalman, Richard S., Agopian, Vatche G., Mehta, Neil, Parikh, Neehar D., Singal, Amit G., and Yang, Ju Dong

Published
2024
Full Text
View/download PDF

24. Development and Validation of a Noninvasive Model for the Detection of High-Risk Varices in Patients with Unresectable HCC

Author

Parikh, Neehar D., Jones, Patricia, Salgia, Reena, Bhan, Irun, Grinspan, Lauren T., Jou, Janice H., Zhou, Kali, Jalal, Prasun, Roccaro, Giorgio, Rangnekar, Amol S., Benhammou, Jihane N., Pillai, Anjana, Mehta, Neil, Wedd, Joel, Yang, Ju Dong, Kim, Amy K., Duarte-Rojo, Andres, Oloruntoba, Omobonike O., Tevar, Amit, Au, Jennifer S., Blain, Yamile, Rao, Sanjana, Catalano, Onofrio A., Lewis, Sara, Mendiratta-Lala, Mishal, King, Kevin, Sachdev, Lekha, Lee, Edward W., Bruno, Jill, Kamel, Ihab, Tolosa, Celestina, Kao, Karissa, Badawi, Tarek, Przybyszewski, Eric M., Quirk, Lisa, Nathani, Piyush, Haydel, Brandy, Leven, Emily, Wong, Nicole, Albertian, Robert, Chen, Ariana, Aloor, Fuad Z., Mohamed, Islam B., Elkheshen, Ahmed, Marvil, Charles, Issac, Gerard, Clinton, Joseph W., Woo, Stephanie M., Yum, Jung, Rieger, Erin, Hutchison, Alan L., Turner, Don A., Alsudaney, Manaf, Hernandez, Perla, Xu, Ziyi, Khalid, Abdullah, Barrick, Bethany, Wang, Bo, Tapper, Elliot B., Hao, Wei, and Singal, Amit G.

Published
2024
Full Text
View/download PDF

28. Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma

Author

Toyoda, Hidenori, Kanneganti, Mounika, Melendez-Torres, Jonathan, Parikh, Neehar D., Jalal, Prasun K., Piñero, Federico, Mendizabal, Manuel, Ridruejo, Ezequiel, Cheinquer, Hugo, Casadei-Gardini, Andrea, Weinmann, Arndt, Peck-Radosavljevic, Markus, Dufour, Jean-Francois, Radu, Pompilia, Shiha, Gamal, Soliman, Riham, Sarin, Shiv K., Kumar, Manoj, Wang, Jing-Houng, Tangkijvanich, Pisit, Sukeepaisarnjaroen, Wattana, Atsukawa, Masanori, Uojima, Haruki, Nozaki, Akito, Nakamuta, Makoto, Takaguchi, Koichi, Hiraoka, Atsushi, Abe, Hiroshi, Matsuura, Kentaro, Watanabe, Tsunamasa, Shimada, Noritomo, Tsuji, Kunihiko, Ishikawa, Toru, Mikami, Shigeru, Itobayashi, Ei, Singal, Amit G., and Johnson, Philip J.

Published
2024
Full Text
View/download PDF

29. The Mortality and Overall Survival Trends of Primary Liver Cancer in the United States

Author

Lee, Yi-Te, Wang, Jasmine J, Luu, Michael, Noureddin, Mazen, Kosari, Kambiz, Agopian, Vatche G, Rich, Nicole E, Lu, Shelly C, Tseng, Hsian-Rong, Nissen, Nicholas N, Singal, Amit G, and Yang, Ju Dong

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Liver Cancer, Rare Diseases, Cancer, Liver Disease, Aging, Digestive Diseases, Good Health and Well Being, Aged, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Carcinoma, Hepatocellular, Cholangiocarcinoma, Humans, Liver Neoplasms, United States, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundRecent trends of hepatocellular carcinoma (HCC) mortality and outcome remain unknown in the United States. We investigated the recent trends of primary liver cancer (excluding intrahepatic cholangiocarcinoma) mortality and HCC stage, treatment, and overall survival (OS) in the United States.MethodsThe National Center for Health Statistics Database was analyzed to investigate the trend of primary liver cancer mortality. We analyzed the Surveillance, Epidemiology, and End Results 18 Database to assess the temporal trend of tumor size, stage, treatment, and OS of HCC. We investigated the association between HCC diagnosis year and OS using Cox regression analysis. All statistical tests were 2-sided.ResultsDuring 2000-2018, liver cancer mortality rates increased until 2013, plateaued during 2013-2016 (annual percent change = 0.1%/y, 95% confidence interval [CI] = -2.1%/y to 2.4%/y, P = .92), and started to decline during 2016-2018 (annual percent change = -1.5%/y, 95% CI = -3.2%/y to 0.2%/y, P = .08). However, mortality continues to increase in American Indian and Alaska Native, individuals aged 65 years or older, and in 33 states. There was a 0.61% (95% CI = 0.53% to 0.69%, P

Published
2021

31. Racial and Ethnic Disparities in Liver Transplantation for Alcohol-associated Liver Diseases in the United States

Author

Cotter, Thomas G., Mitchell, Mack C., Patel, Mausam J., Anouti, Ahmad, Lieber, Sarah R., Rich, Nicole E., Arab, Juan Pablo, Díaz, Luis Antonio, Louissaint, Jeremy, Kerr, Thomas, Mufti, Arjmand R., Hanish, Steven I., Vagefi, Parsia A., Patel, Madhukar S., VanWagner, Lisa B., Lee, William M., O’Leary, Jacqueline G., and Singal, Amit G.

Published
2024
Full Text
View/download PDF

32. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic.

Author

Mehta, Neil, Parikh, Neehar D, Kelley, R Katie, Hameed, Bilal, and Singal, Amit G

Subjects
Humans, Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Recurrence, Local, alpha-Fetoproteins, Pandemics, COVID-19, SARS-CoV-2, AFP, Alpha-Fetoprotein, Coronavirus, HCC, Screening, Liver Disease, Cancer, Prevention, Clinical Research, Rare Diseases, Patient Safety, Digestive Diseases, Liver Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Good Health and Well Being, Clinical Sciences, Gastroenterology & Hepatology
Abstract

The Coronavirus disease 2019 (COVID-19) pandemic is expected to have a long-lasting impact on the approach to care for patients at risk for and with hepatocellular carcinoma (HCC) due to the risks from potential exposure and resource reallocation. The goal of this document is to provide recommendations on HCC surveillance and monitoring, including strategies to limit unnecessary exposure while continuing to provide high-quality care for patients. Publications and guidelines pertaining to the management of HCC during COVID-19 were reviewed for recommendations related to surveillance and monitoring practices, and any available guidance was referenced to support the authors' recommendations when applicable. Existing HCC risk stratification models should be utilized to prioritize imaging resources to those patients at highest risk of incident HCC and recurrence following therapy though surveillance can likely continue as before in settings where COVID-19 prevalence is low and adequate protections are in place. Waitlisted patients who will benefit from urgent LT should be prioritized for surveillance whereas it would be reasonable to extend surveillance interval by a short period in HCC patients with lower risk tumor features and those more than 2 years since their last treatment. For patients eligible for systemic therapy, the treatment regimen should be dictated by the risk of COVID-19 associated with route of administration, monitoring and treatment of adverse events, within the context of relative treatment efficacy.

Published
2021

34. A Real‐World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET‐HCC

Author

Cabrera, Roniel, Singal, Amit G, Colombo, Massimo, Kelley, R Kate, Lee, Hannah, Mospan, Andrea R, Meyer, Tim, Newell, Pippa, Parikh, Neehar D, Sangro, Bruno, Reddy, K Rajender, Watkins, Stephanie, Zink, Richard C, and Di Bisceglie, Adrian M

Subjects
Cancer, Hepatitis, Liver Disease, Liver Cancer, Chronic Liver Disease and Cirrhosis, Clinical Research, Clinical Trials and Supportive Activities, Digestive Diseases, Rare Diseases, Good Health and Well Being, Adult, Aged, Carcinoma, Hepatocellular, Europe, Female, Health Services Research, Humans, Liver Neoplasms, Longitudinal Studies, Male, Middle Aged, Outcome Assessment, Health Care, Prospective Studies, Research Design, United States
Abstract

This study describes the design of the TARGET-hepatocellular carcinoma (HCC) cohort and descriptive characteristics of the patient population at diagnosis among those who were enrolled in the cohort across academic and community clinical centers. TARGET-HCC is a 5-year, longitudinal, observational cohort of patients with HCC receiving care in usual clinical practice. Redacted clinical information, obtained from medical records, captures the natural history and management of the disease, including the safety and efficacy of treatment interventions used in usual clinical practice. Patients can complete patient-reported outcome measures and provide biological specimens for future translational studies. The TARGET-HCC study includes adults with histologic, cytologic, or radiologic diagnosis of HCC from academic and community centers in both the United States and Europe. A total of 1,841 participants were enrolled between January 9, 2017, and July 23, 2019, at 67 sites in the United States and Europe. To date, the most common liver disease etiology in the cohort continues to be hepatitis C, although nearly half had a nonviral etiology, including alcohol-related liver disease or nonalcoholic steatohepatitis. Most included patients were diagnosed at an early stage (Barcelona Clinic Liver Cancer Stage [BCLC] 0/A), but only approximately one third underwent curative treatment. Systemic therapy has been used in 7.3% of enrolled patients, including 45.7% of those with BCLC stage C tumors. Conclusion: Overall, the TARGET-HCC cohort allows for the assessment of patient characteristics and investigation of new treatment paradigms and sequencing with existing agents as well as novel regimens for HCC.

Published
2021

35. Comparison of Surgical Resection and Systemic Treatment for Hepatocellular Carcinoma with Vascular Invasion: National Cancer Database Analysis

Author

Govalan, Rajalakshmi, Lauzon, Marie, Luu, Michael, Ahn, Joseph C, Kosari, Kambiz, Todo, Tsuyoshi, Kim, Irene K, Noureddin, Mazen, Kuo, Alexander, Walid, Ayoub S, Sundaram, Vinay, Lu, Shelly C, Roberts, Lewis R, Singal, Amit G, Heimbach, Julie K, Agopian, Vatche G, Nissen, Nicholas, and Yang, Ju Dong

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Digestive Diseases, Patient Safety, Cancer, Liver Cancer, Rare Diseases, Liver Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, Hepatocellular carcinoma, Vascular invasion, Surgical resection, Prognosis
Abstract

IntroductionSmall studies from outside of the USA suggest excellent outcomes after surgical resection for hepatocellular carcinoma (HCC) with vascular invasion. The study aims to (1) compare overall survival after surgical resection and systemic therapy among patients with HCC and vascular invasion and (2) determine factors associated with receipt of surgical resection in a US population.MethodsHCC patients with AJCC clinical TNM stage 7th T3BN0M0 diagnosed between 2010 and 2017 from the National Cancer Database were analyzed. Cox and logistic regression analyses identified factors associated with overall survival and receipt of surgical resection.ResultsOf 11,259 patients with T3BN0M0 HCC, 325 (2.9%) and 4,268 (37.9%) received surgical resection and systemic therapy, respectively. In multivariable analysis, surgical resection was associated with improved survival compared to systemic therapy (adjusted hazard ratio: 0.496, 95% confidence interval: 0.426-0.578) with a median survival of 21.4 and 8.1 months, respectively. Superiority of surgical resection was observed in noncirrhotic and cirrhotic subgroups and propensity score matching and inverse probability of treatment weighting adjusted analysis. Asians were more likely to receive surgical resection, whereas Charlson comorbidity ≥3, elevated alpha-fetoprotein, smaller tumor size, care in a community cancer program, and the South or West region were associated with a lower likelihood of surgical resection.ConclusionHCC patients with vascular invasion may benefit from surgical resection compared to systemic therapies. Demographic and clinical features of HCC patients and region and type of treating facility were associated with surgical resection versus systemic treatment.

Published
2021

36. Effectiveness and safety of atezolizumab-bevacizumab in patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis

Author

Kulkarni, Anand V., Tevethia, Harshvardhan, Kumar, Karan, Premkumar, Madhumita, Muttaiah, Mark D., Hiraoka, Atsushi, Hatanaka, Takeshi, Tada, Toshifumi, Kumada, Takashi, Kakizaki, Satoru, Vogel, Arndt, Finn, Richard S., Rao, Padaki Nagaraja, Pillai, Anjana, Reddy, Duvvur Nageshwar, and Singal, Amit G.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results